stocktools
Offerings // Inhibrx Biosciences, Inc.

INBX offering history

Every offering-related filing in Inhibrx Biosciences, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 132 filings back to Jan 29, 2024.

Last executed offering
Jul 16, 2026
8-K — priced deal (shares or notes)
Last registration (announced)
Jun 11, 2024
S-1 — capacity, not a sale
Executed, last 12 months
1
424B pricings + 8-K 3.02 sales
Registered, last 12 months
0
S-1/S-3/F-series registrations
DateFilingWhat it means
Jul 16, 20268-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jun 4, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
May 28, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
May 14, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Apr 18, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Apr 1, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Mar 17, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jan 21, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jan 13, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jan 13, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Nov 14, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Nov 4, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Aug 14, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Aug 13, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jun 18, 2024424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jun 18, 2024EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Jun 11, 2024S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
May 30, 20248-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
INBX offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full INBX workspace →
INBX offering FAQ

When did INBX last execute an offering?

Per SEC filings, Inhibrx Biosciences, Inc.'s most recent priced offering document is a 8-K filed 2026-07-16. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did INBX last announce or register an offering?

The most recent registration is a S-1 filed 2024-06-11. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.